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Abstract
The family of Toll-like receptors (TLRs) is critical in linking innate and acquired immunity. Polymorphisms in the genes
encoding TLRs have been associated with autoimmune diseases and cancer. We investigated the genetic variation of TLR
genes and its potential impact on melanoma susceptibility and patient survival. The study included 763 cutaneous
melanoma cases recruited in Germany and 736 matched controls that were genotyped for 47 single nucleotide
polymorphisms (SNPs) in 8 TLR genes. The relationship between genotype, disease status and survival was investigated
taking into account patient and tumor characteristics, and melanoma treatment. Analysis of 7 SNPs in TLR2, 7 SNPs in TLR3
and 8 SNPs in TLR4 showed statistically significant differences in distribution of inferred haplotypes between cases and
controls. No individual polymorphism was associated with disease susceptibility except for the observed tendency for TLR2-
rs3804099 (odds ratio OR =1.15, 95% CI 0.99–1.34, p=0.07) and TLR4-rs2149356 (OR=0.85, 95% CI 0.73–1.00, p=0.06). Both
polymorphisms were part of the haplotypes associated with risk modulation. An improved overall survival (Hazard ratio HR
0.53, 95% CI 0.32–0.88) and survival following metastasis (HR 0.55, 95% CI 0.34–0.91) were observed in carriers of the variant
allele (D299G) of TLR4-rs4986790. In addition various TLR2, TLR4 and TLR5 haplotypes were associated with increased overall
survival. Our results point to a novel association between TLR gene variants and haplotypes with melanoma survival. Our
data suggest a role for the D299G polymorphism in the TLR4 gene in overall survival and a potential link with systemic
treatment at stage IV of the disease. The polymorphic amino acid residue, located in the ectodomain of TLR4, can have
functional consequences.
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Introduction
Malignant melanoma, with its propensity to metastasize and
chemoresistance, remains a fatal neoplasm. Spontaneous regression,
a phenomenon likely mediated by the immune system, is more
common in melanoma than in most other cancers. The role of host
immune system in melanoma is evidenced by the association of
autoimmuneconditionssuchasthyroiditis,vitiligoortheappearance
of autoantibodies with an improved prognosis in patients treated
with interleukin 2 and/or interferon a therapy [1,2,3,4]. Variations
in genes involved in critical pathways of the immune system might
therefore influence the susceptibility to autoimmune diseases and
subsequently melanoma susceptibility, progression and prognosis.
Toll-like receptors (TLR), the mammalian homologues of the
Drosophila Toll protein, are perceived to be sensors for recognition
of a number of invading pathogens.
TLR are critical in linking innate and acquired immunity and in
serving as detectors of infectious pathogens and cancer debris
[5,6,7]. TLRs belong to the family of pattern-recognition receptors
(PRRs) which are expressed, among others, on antigen-presenting
cells like dendritic cells or T-cells. After induction through
pathogen-associated molecules, TLRs transduce signals via distinct
intracellular pathways leading to the activation of transcription
factors such as NFkB, interferon regulatory factors (IRFs) or AP-1.
Finally these transcription receptors trigger inflammatory respons-
es such as the release of inflammatory cytokines and type I
interferons [7,8,9].
PolymorphismsingenesencodingTLRassociated withinfectious
and non-infectious diseases, including autoimmunity and cancer,
have been studied extensively [10,11,12,13]. However, the variants
in the genes have not been investigated for association with either
melanoma susceptibility or disease outcome. In order to investigate
the effect of polymorphisms in the TLR genes on melanoma
susceptibility and survival, we genotyped 47 single nucleotide
polymorphisms (SNP) in eight TLR genes in 763 cases from
Germany and 736 ethnically matched controls.
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The two multiplex reactions contained 373 replicates from
different SNPs that showed a concordance rate over .99%. The
rate of undetermined samples by the Sequenom procedure was
between 6 and 33% of the individual SNPs. Genotype distribu-
tions of all polymorphisms in controls did not show statistically
significant deviation from Hardy-Weinberg equilibrium.
Out of 47TLR SNPs analyzed by Sequenom mass spectrometry
TLR1-rs3923647 and TLR1-rs5743613, TLR2-rs5743704 and -
rs5743708, TLR4-rs11536869 and -rs11536897 and TLR6-
rs5743815 had minor allele frequencies ,0.05; no carrier of
variant allele for TLR9-rs5743846 was detected. In total, the
genotyping results of 47 SNPs represent 99 polymorphisms in the
selected TLR genes.
Case-control study
We did not observe any differences in the distribution of allele
and genotype frequencies between melanoma cases and controls
(Table S1, online only). The variant allele for TLR2-rs3804099
was associated with an increased risk (OR=1.15, 95% CI 0.99–
1.34, p=0.07) and for TLR4-rs2149356 with a decreased risk
(OR=0.85, 95% CI 0.73–1.00, p=0.06) of melanoma. However,
for both, the association was not statistically significant.
Haplotype analysis
Analysis of 7 SNPs in TLR2, 7 SNPs in TLR3 and 8 SNPs in
TLR4 showed statistically significant differences in distribution of
inferred haplotypes between cases and controls (Table 1). The
haplotype A-C-C-C-C-G-T of the TLR2 gene locus was associated
with an increased risk compared to the consensus haplotype A-C-
C-C-T-G-T (OR 1.31, 95%CI 1.03–1.65). This haplotype
included the SNP that showed individually an association with
increased risk. A haplotype for the TLR3 gene (C-G-G-T-A-G-G)
was associated with a decreased susceptibility to melanoma (OR
0.57, 95%CI 0.35–0.95) compared to the most frequent haplotype
(C-G-A-C-C-C-A). The haplotype A-T-A-G-A-G-G-C of the
TLR4 gene locus associated with a decreased risk for melanoma
compared to the most frequent haplotype A-T-C-A-A-G-G-T (OR
0.72, 95%CI 0.57–0.91). The haplotype includes the minor allele
of TLR2-rs2149356 that associated individually with a protective
effect. Haplotype analysis of the other TLRs did not identify
associations with melanoma risk (data not shown).
Polymorphisms in TLR genes and survival
Differences in survival according to genotype were investigated
based on 622 patients with melanoma of the skin with known
primary at first diagnosis without detectable metastasis (stage I/II)
(339 males and 283 females out of 763 patients in total).
The OS from primary diagnosis was better in carriers of the
minor allele (n=81) of the TLR4-rs4986790 polymorphism than
among non-carriers (n=536). The median OS in carriers was 18.1
years (95% CI 12.1–24.4) compared to 11.0 years (95% CI 9.5–
12.9) in non-carriers (log-rank p=0.005, Figure 1A and Table 2).
Cox regression adjusted for age, gender and Breslow thickness
showed a decreased survival with a HR of 0.53, 95% CI 0.32–0.88,
p=0.01,Table 2)forcarriersoftheminorallele.Adjustmentforany
kind of therapy in stage IV showed no effect on this estimate (HR
0.53, 95% CI 0.32–0.87, p=0.01, Table 2). Stratification according
to therapy showed that the HR was 0.41 (95% CI 0.24–0.69,
p=0.001) among patients receiving any therapy, compared to HR
0.35 (95% CI 0.05–2.59, p=0.30) for patients that did not receive
any therapy. The statistical non-significance in the latter could be
attributed to small patient numbers.
The TLR4-rs4986790 polymorphism was also associated with
survival time following first metastasis (SFM). Carriers of the
minor allele displayed a median SFM of 7.1 years (95% CI 3.3–
11.1) compared to 2.8 years (95% CI 2.1–3.5) for non-carrier
patients (log-rank p=0.01, Figure 1B and Table 2). The effect was
reflected in the Cox regression model with a HR of 0.55 (95% CI
0.33–0.91, p=0.02) and adjustment for any therapy slightly
decreased the estimate (HR 0.44, 95% CI 0.27–0.73, p=0.001,
Table 2). The stratification for therapy showed a statistically
significant effect (HR 0.39, 95% CI 0.23–0.66, p=0.001) only in
patients that received therapy and not in patient that did not
Table 1. Distribution of the most common haplotypes within
TLR2, TLR3 and TLR4 in German melanoma patients and
German controls.
Gene Haplotype Cases (%) Controls (%) OR (95% CI) P
TLR2 A-C-C-C-T-G-T 197 (12.9) 220 (15.0) Reference 1.0
T-C-A-C-T-G-T 491 (32.3) 496 (33.8) 1.11 (0.88–1.39)
A-C-C-C-C-G-T 457 (30.0) 391 (26.7) 1.31 (1.03–
1.65)
T-T-C-C-C-G-T 140 (9.2) 141 (9.6) 1.11 (0.82–1.50)
A-C-C-C-C-G-C 94 (6.2) 85 (5.8) 1.23 (0.87–1.75)
A-C-C-A-T-G-T 48 (3.2) 51 (3.5) 1.05 (0.68–1.63)
T-C-A-C-T-A-T 38 (2.5) 33 (2.2) 1.29 (0.78–2.13)
T-C-C-C-T-G-T 29 (1.9) 24 (1.6) 1.35 (0.76–2.40)
T-T-C-C-T-G-T 12 (0.8) 11 (0.7) 1.22 (0.53–2.82)
other 16 (1.0) 15 (1.0) 2
TLR3 C-G-A-C-C-C-A
3 268 (17.6) 256 (17.5) Reference 0.94
C-A-G-C-C-G-G 240 (15.8) 211 (14.4) 1.09 (0.84–1.40)
C-G-G-T-A-C-G 205 (13.5) 187 (12.8) 1.05 (0.81–1.36)
C-G-G-C-A-C-G 153 (10.1) 176 (12) 0.83 (0.63–1.09)
T-G-G-C-C-C-G 215 (14.2) 175 (12) 1.17 (0.90–1.53)
C-G-G-C-C-C-A 123 (8.1) 128 (8.7) 0.92 (0.68–1.24)
C-A-G-C-C-C-G 91 (6.0) 77 (5.3) 1.13 (0.80–1.60)
C-G-A-C-C-C-G 71 (4.7) 75 (5.1) 0.90 (0.63–1.31)
C-G-G-T-A-G-G 27 (1.8) 45 (3.1) 0.57 (0.35–
0.95)
C-G-G-C-C-C-G 44 (2.9) 33 (2.3) 1.27 (0.79–2.06)
C-G-G-C-C-G-G 16 (1.1) 20 (1.4) 0.76 (0.39–1.51)
T-G-G-C-C-C-A 13 (0.9) 14 (1.0) 0.89 (0.41–1.92)
C-G-G-C-C-G-A 16 (1.1) 13 (0.9) 1.18 (0.55–2.49)
other 37 (2.4) 53 (3.6) 2
TLR4 A-T-C-A-A-G-G-T
3 457 (30) 405 (27.5) Reference 0.95
A-C-C-G-A-G-G-T 371 (24.4) 357 (24.3) 0.92 (0.76–1.12)
A-T-A-G-A-G-G-C 192 (12.6) 237 (16.1) 0.72 (0.57–
0.91)
A-C-C-G-A-C-G-T 209 (13.7) 215 (14.6) 0.86 (0.68–1.09)
A-T-A-G-G-G-G-C 85 (5.6) 77 (5.2) 0.98 (0.7–1.37)
G-T-A-G-A-G-G-T 43 (2.8) 52 (3.5) 0.73 (0.48–1.12)
A-T-A-G-A-G-G-T 60 (3.9) 40 (2.7) 1.33 (0.87–2.03)
A-T-A-G-A-G-A-C 50 (3.3) 39 (2.6) 1.14 (0.73–1.76)
A-C-A-G-A-G-G-T 8 (0.5) 10 (0.7) 0.71 (0.28–1.81)
other 46 (3.0) 40 (2.7) 2
doi:10.1371/journal.pone.0024370.t001
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TLR4-rs4986790 polymorphism did not associate with time from
primary diagnosis to first metastasis (Table 2).
Carriers of the variant allele of TLR2-rs3804100 (TC/CC) also
showed a reduced OS (HR 0.55, 95% CI 0.29–1.05, p=0.07).
Adjustment for any therapy at any clinical stage did not show an
Figure 1. Overall survival (OS) and survival after metastasis (SFM) in German cutaneous melanoma patients according to theTLR4-
rs4986790 (D299G) genotype. The Kaplan-Meier curves differentiate between carriers of the minor allele (AG+GG) and homozygote genotypes
(AA) for (A) overall survival, log-rank P=0.005 and (B) survival following the first metastasis, log-rank P=0.01. Number of patients, both carriers and
non-carriers, is given below the x-axis.
doi:10.1371/journal.pone.0024370.g001
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the possible interaction between polymorphisms TLR4-rs4986790
and TLR2-rs3804100 regarding OS. Patients with the commonest
genotype (rs4986790=AA, rs3804100=TT) showed the poor-
est prognosis. Among 13 patients with rs4986790=AG and
rs3804100=TC/CC, no death was observed ten years after
diagnosis. The survival heterogeneity among the four categories of
individuals resulted in a probability value from the log-rank test of
0.01, which increased to 0.03 after inclusion of age, gender and
Breslow thickness in a subsequent Cox regression. Other investi-
gated polymorphisms did not associate with OS, SFM or MFS.
Association of TLR haplotypes with overall survival
Several haplotypes inferred based on polymorphisms in TLR2,
TLR4 and TLR5 showed association with OS (Table 3). In the
TLR2 gene, a minor haplotype A-C-C-C-C-G-C (5.5%) was
significantly associated with an increased survival compared to the
consensus haplotype A-C-C-C-T-G-T (HR 0.46, 95% CI 0.22 -
0.95). Another haplotype in TLR4, A-T-A-G-A-G-G-T, associated
with OS (HR 1.77, 95% CI 1.02–3.08) in comparison to the most
frequent haplotype. A frequent haplotype of TLR4 (A-T-A-G-A-
G-G-C, 13.9%) also associated with increased OS (HR 1.4, 95%
CI 0.95–2.06). Out of the 5 major TLR5 haplotypes, one
associated with enhanced OS (T-T-G-C, HR 1.6, 95% CI 1.05–
2.43). The remaining TLR haplotypes did not show significant
association with OS (data not shown).
TLR Haplotype associations with survival time following
first metastasis
The TLR2 haplotype T-T-C-C-C-G-T (9.6%) was associated
with an increased SFM compared to the common haplotype (HR
1.54 95% CI 1.04–2.28). Other significant associations with
decreased SFM were seen for TLR4- A-T-A-G-A-G-A-C and
TLR4-G-T-A-G-A-G-G-T (HR 0.36, 95% CI 0.14–0.90 and HR
2.41, 95% CI 1.10–5.24), which were both rare (3.1% and 2.7%,
respectively). Two frequent haplotypes A-C-C-G-A-G-G-T and A-
T-A-G-A-G-G-C (26.2% and 14.1%, respectively) in this gene
were associated with decreased SFM (HR 1.36, 95% CI 0.97–1.92
and HR 1.47, 95% CI 0.99–2.19, respectively). No other of the
TLR haplotypes showed association with SFM.
TLR Haplotype associations with metastasis free survival
(MFS) after diagnosis of primary tumor
Patients that harbored the TLR4 haplotype A-T-A-G-A-G-G-T
were at an increased risk for MFS compared to those carrying the
most frequent haplotype A-T-C-A-A-G-G-T (HR 2.02, 95% CI
1.28–3.17). Significant association with MFS was also seen for one
of the most frequent haplotypes (C-G-G-C, frequency 26.5%) of
the TLR5 gene when compared to the consensus haplotype C-T-
G-C (HR 1.39, 95% CI 1.03–1.88). Other associations of TLR
haplotypes with MFS were not statistically significant.
Discussion
TLRs, the mammalian homologues of Drosophila toll protein,
play a role as agents of innate and adaptive immunity in various
diseases. We assumed that genetic polymorphisms in various TLRs
were functional and influenced melanoma susceptibility and
disease outcome. Our data showed that melanoma patients
carrying the variant allele for the rs4986790 polymorphism in
the TLR4 gene were associated with a prolonged OS. The increase
in survival was confined to the period after the detection of a first
metastasis, which implied that the effect of the polymorphism
might possibly modulated dependent on therapy or alternatively
by biological processes associated with melanoma cell migration
and/or invasion. The patients in stage IV melanoma in most
instances received a chemotherapy containing DTIC/temozolo-
mide and interferons, which is known for long time not having any
clinical effect on overall survival of the entire metastatic melanoma
population [14,15].
One can speculate that the prolonged survival after first
metastasis, which clinically is in most cases regionally spread, is
mediated by more efficacious tumor control at the lymph node
level and by interaction with the immune system.
TLR4-rs4986790 polymorphism results in a change of amino
acid D299G and it co-segregates with a T399I exchange, which
are both located in the ectodomain of TLR4 [16]. The
ectodomain of TLR4 is responsible for detecting of lipopolysac-
charides from Gram negative bacteria in cooperation with an
accessory molecule, myeloid differentiation factor 2 (MD-2). MD-2
forms a 1:1 complex with lipopolysaccharides, which is detected by
TLR4 [16]. Interestingly, the amino acid residues 299 and 399 of
TLR4 are not located either in the recognition surface of TLR4
for the MD-2-lipopolysaccharide complex or on the surface
required for receptor dimerization. Nevertheless, both polymor-
phisms reduce responsiveness to lipopolysaccharides as shown in
tissue culture systems with re-constituted TLR4 mutants [17].
Apart from bacterial lipopolysaccharides, TLR4 was shown to be
activated by host high mobility group box 1 protein (HMGB-1)
released as a result of chemo- or radiotherapy, and potential tissue
damage [18]. In that study, on French breast cancer patients, the
Table 2. TLR4-rs4986790 genotype and overall survival (OS), survival following the first metastasis (SFM) and metastasis free
survival (MFS).
Genotype Individuals
Median survival in years
(95% CI)
Uncensored
events (%) Hazard Ratio (95% CI) P
OS AA 536 11.0 (9.5–12.9) 161 (30.0) Reference
AG 81 18.1 (12.1–24.4) 19 (23.5) 0.53 (0.32–0.88) 0.01
0.53 (0.32–0.87) 0.01
MFS AA 536 7.2 (5.5–8.3) 239 (44.6) Reference
AG 81 10.6 (3.2–20.3) 39 (48.1) 0.81 (0.55–1.18) 0.27
SFM AA 222 2.8 (2.1–3.5) 144 (64.9) Reference
AG 39 7.1 (3.3–11.1) 19 (46.2) 0.55 (0.33–0.91) 0.02
0.44 (0.27–0.73) 0.001
doi:10.1371/journal.pone.0024370.t002
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correlation with faster relapse after radiotherapy [18]. It is
interesting to speculate whether HMGB1, released as a conse-
quence of tissue necrosis or therapy, results in genotype dependent
differential activation of TLR4, which contributes to the observed
differences in survival. Further patient-based and functional
studies, will be required to confirm the correlation between
polymorphisms and survival. It is also worth noting that colon
cancer patients carrying the minor allele of TLR4-rs4986790
exhibited worse progression free survival and OS after treatment
with chemotherapy [19]. On the other hand, a comprehensive
Swedish study on 20 TLR signaling pathway genes found
significant association between two polymorphisms with prostate
cancer mortality that did not include TLR4-rs4986790 [20]. Thus,
even if modulated HMGB-1 signaling might be due to the effects
of TLR4-rs4986790, the outcome in terms of OS is difficult to
predict as the TLR ligation can have pleiotropic effects on cellular
differentiation and growth.
With the exception of two polymorphisms, TLR2-rs3804099
and TLR4-rs2149356, none other of the 47 variants in eight TLR
genes included in this study showed association with risk of
melanoma in comparison to the healthy controls. The variant
alleles of the two polymorphisms showed a tendency towards
association with susceptibility but not strong enough to rule out a
chance finding. Nevertheless, previous reports have shown
associations of the rs3804099 polymorphism in the TLR2 gene
with sepsis in preterm infants [21]. It was also associated with
reversal reaction in leprosy and tuberculosis in Ethiopian and
Vietnamese populations [22,23]. On the other hand no association
of this SNP could be found with normal tension glaucoma in a
Japanese population or asthma in a German and a mixed
German/Austrian population or type I diabetes mellitus in a
Basque population [24,25,26,27]. Since the polymorphism is
synonymous (N199N) and not linked with any other variant in the
gene, the association with various diseases could be due to linkage
with other SNPs outside the TLR2 gene region. The most
commonly discussed polymorphisms in TLR2, the R677W and
R753Q, have been shown to be associated, amongst other
diseases, with leprosy, tuberculosis, staphylococcal infections,
coronary restenosis and sepsis [11,12]. In our study the R677W
could not be included due to immeasurable genotype, probably
caused by a pseudogene located upstream of the true gene [28].
The R753Q variant was rather rare and did not show any
association with melanoma susceptibility.
The variant allele of TLR4-rs2149356, exhibited association
with decreased risk of melanoma that was not statistically
significant. However, the haplotype containing the same variant
allele was associated with statistically significant decreased risk.
TLR4-rs2149356 is located in intron 2 of the gene and is linked
with four other polymorphisms at the locus. One of which is
located in intron 1 (rs1927911) and three (rs10116253, rs2737190,
rs1927914) in the 59end of the gene. Therefore it is possible that
SNPs in the 59 end could possibly effect transcriptional regulation.
In previous studies variants in the TLR4 gene have been shown to
be associated with infectious and non-infectious diseases but rather
inconsistently [10,29,30,31].
Table 3. Overall survival according to the commonest TLR2, TLR4 and TLR5 haplotypes.
Gene Haplotype Frequency (%) Uncensored events (%) HR (95% CI) P
TLR2 A-C-C-C-T-G-T 121 (11.2) 37 (3.4) Reference 0.11
T-C-A-C-T-G-T 367 (33.9) 105 (9.7) 0.86 (0.60–1.24)
A-C-C-C-C-G-T 345 (31.9) 100 (9.2) 0.84 (0.58–1.24)
T-T-C-C-C-G-T 104 (9.6) 32 (3.0) 1.07 (0.67–1.73)
A-C-C-C-C-G-C 59 (5.5) 9 (0.8) 0.46 (0.22–0.95)
A-C-C-A-T-G-T 33 (3.0) 8 (0.7) 0.62 (0.28–1.36)
T-C-A-C-T-A-T 20 (1.8) 1 (0.1) 0.24 (0.03–1.78)
T-C-C-C-T-G-T 20 (1.8) 4 (0.4) 0.58 (0.21–1.65)
other 13 (1.2) 6 (0.6) 2
TLR4 A-T-C-A-A-G-G-T
3 323 (29.9) 82 (7.6) Reference 0.12
A-C-C-G-A-G-G-T 268 (24.8) 85 (7.9) 1.09 (0.77–1.53)
A-T-A-G-A-G-G-C 150 (13.9) 47 (4.3) 1.40 (0.95–2.06)
A-C-C-G-A-C-G-T 139 (12.9) 35 (3.2) 1.01 (0.67–1.50)
A-T-A-G-G-G-G-C 68 (6.3) 17 (1.6) 0.60 (0.35–1.04)
A-T-A-G-A-G-G-T 40 (3.7) 16 (1.5) 1.77 (1.02–3.08)
A-T-A-G-A-G-A-C 32 (3.0) 5 (0.5) 0.44 (0.18–1.10)
G-T-A-G-A-G-G-T 29 (2.7) 9 (0.8) 1.73 (0.83–3.60)
other 33 (3.1) 6 (0.6) 2
TLR5 C-T-G-C
3 241 (22.3) 61 (5.7) Reference 0.32
C-T-C-C 395 (36.6) 108 (10.0) 1.18 (0.85–1.63)
C-G-G-C 287 (26.6) 86 (8.0) 1.33 (0.91–1.93)
T-T-G-C 96 (8.9) 35 (3.2) 1.60 (1.05–2.43)
C-T-C-T 53 (4.9) 12 (1.1) 0.96 (0.51–1.83)
other 8 (0.7) 1 (0.1) 2
doi:10.1371/journal.pone.0024370.t003
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malignant melanoma show an association of one variant in the
TLR4 gene with the disease survival. Though we did not find any
clear association for any polymorphism with the disease suscep-
tibility, for two SNPs we did find a tendency for such an




763 patients of German origin (418 male, 345 female) with
cutaneous melanoma were recruited at the Skin Cancer Unit at the
Mannheim University Hospital, Germany, according to eligibility
criteria that includedhistologicallyconfirmed melanomaof the skin;
AJCC stage 0 (in situ melanoma, 10), I (358), II (253), III (112) and
IV (11) disease and 19 tumors had an unknown stage (Table 4).
Median and mean age of the melanoma cases at diagnosis was 55
and 54.1 years, respectively. Mean Breslow thickness was 2.14 mm
(95% confidence interval 1.97 to 2.31 mm).
Blood samples from case subjects were taken during the first
appointment at the Skin Cancer Unit. Controls included 736
healthy individuals (368 male and 368 female) recruited at the
Institute of Transfusion Medicine and Immunology in Mannheim,
Germany. Median and mean age of the controls were 61 and 60.3
years, respectively. The ethical approval for the study was granted
by Ethics Commission of the Faculty for Clinical Medicine of
Ruprecht-Karls-Universita ¨t, Heidelberg and written informed
consent was obtained from all study participants. DNA was
extracted from blood samples using Qiagen mini-preparation kits.
Selection of SNPs
Selection of SNPs in eight human TLR genes was done by
inclusion of known non-synonymous SNPs, those in regulatory
regions or reported by other investigators. Additionally tagging
SNPs for each gene region were selected from HapMap data using
the criteria, a) exclusion of individuals with .50% missing
genotypes, b) pair-wise r
2.0.8 for each SNP pair and c) minor
allele frequencies .5%. Of the eight TLR genes, three were
located in a gene cluster on chromosome 4p14 (TLR6-TLR1-
TLR10). For tagging analysis, the region from rs10024216 to
rs6531668 (69.5 kb) was selected (Figure S1, online only). TLR2
and TLR3 are located on chromosome arm 4q; these two genes
were about 32 Mb apart from each other and were not linked.
TLR4 is on chromosome 9q23; TLR5 on 1q41 and TLR9 on
3p21. In total we selected 47 SNPs that were informative for 99
polymorphisms in 8 genes. The selected SNPs were grouped into 2
multiplex assays (W1 and W2) for the Sequenom mass array
platform (Sequenom, San Diego, CA, USA, Table S2 and S3,
online only). In addition, the TLR4-rs4986790 (D299G) SNP was
selected for genotyping using an allelic discrimination method.
Genotyping
Genotyping was carried out with the Sequenom method. In two
multiplex PCR (with the 25 or 23 primer pairs, respectively) DNA
fragments with SNPs were amplified using 10 ng DNA as template
in 5 ml volume. Genotype analysis was performed by the
Sequenom TYPER 4.0 software. Validation of genotype data for
SNPs that showed statistically significant association (TLR2-
rs3804099 and TLR4-rs2149356) was done by allelic discrimina-
tion method and DNA sequencing.
Statistical analysis
All statistical calculations were carried out using SAS version 9.2
(SAS Institute, Cary, NC, USA). Odds ratios (OR) with the
corresponding 95% confidence intervals (95% CI) for assessment
of the association between risk and genotype were based on logistic
regression adjusted for age, gender and Breslow thickness. The
haplotype procedure of SAS genetics was used to estimate
haplotype frequencies in cases and controls separately, and to
infer possible haplotype combinations for each individual. The
evidence of association between genotype/haplotype and mela-
noma risk were summarized by probability values.
Overall survival (OS) was defined as the time (in years) from
date of first diagnosis until death or last patient contact. Metastasis
free survival (MFS) was the time from diagnosis of primary
melanoma until the first metastasis (either regional or distant).
Survival following first metastasis (SFM) was defined as the time
from first metastasis to death or last patient contact. Alive patients
at the latest visit/contact were considered censored. Univariate
survival curves were based on the Kaplan-Meier method and
statistical significance was quantified by log-rank tests. Genotype-
specific survival differences were adjusted for age, gender and
Breslow thickness, based on a proportional hazard regression








Male 418 (54.8%) 341 (38.8%)
Female 345 (45.2%) 281 (45.2%)




Mean (95% CI) 2.14 (1.97–2.31) 1.81 (1.66–1.96)
Ulceration of primary tumor
Yes 130 (17.0)%) 92 (14.8%)
No 185 (24.3%) 159 (25.6%)
unknown 448 (58.7) 371 (59.7%)
AJCC stage at FD
0 10 (1.3%) 10 (1.6%)
I 396 (51.9%) 396 (63.7%)
II 216 (28.3%) 216 (34.7%)
III 111 (14.6%) 2
IV 11 (1.4%) 2
unknown 19 (2.5%) 2
Metastasized during follow-up 237 (31.1%) 237 (38.1%)%)
Deceased during follow-up 170 (22.3%) 127 (20.4%)
Therapy
No therapy 408 (53.5%) 364 (58.5%)
Any therapy 353 (46.3%) 258 (41.5%)
Chemotherapy 28 (3.7%) 17 (2.7%)
Immunotherapy 129 (16.9) 98 (15.8%)
All other therapy combinations 199 (26.1%) 143 (23.0%)
doi:10.1371/journal.pone.0024370.t004
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not included in the multivariate analysis due to unavailability of
complete data. Subsequently, the analysis of the potential
association between genotype and survival was adjusted for
therapy administered in stage IV. We considered the start time
and duration of therapy, treating therapy as a time-dependent
covariate. The possible interaction between therapy and genotype
was explored by including the interaction in the Cox regression
and, additionally, by stratification of patients into therapy groups.
Association of haplotypes with survival time was carried out by
Cox regression. Thereby, we assumed that individuals carry the
most likely combination of possible haplotypes and that the effects
of haplotypes interact multiplicatively. Hazard ratios (HR) were
calculated taking the consensus haplotype as reference. If the
frequency of the consensus haplotype was low, the most common
haplotype was taken as reference.
Supporting Information
Figure S1 Linkage disequilibrium (LD) plot of the 69-kb
TLR6-TLR1-TLR10 gene cluster on chromosome 4p14.
The plot was drawn using Haploview software 4.2 and based on
HapMap homepage. It shows r
22values, the higher r
2, the darker
the box. LD blocks are depicted as triangles. Positions of the TLR
genes and SNPs are shown in the upper part of the figure.
(DOC)
Table S1 Genotype distributions of TLR SNPs in
malignant melanoma of the skin in patients and
controls.
(DOC)
Table S2 Toll-like receptor genes and polymorphisms.
(DOC)
Table S3 List of iplex primer and masses.
(XLS)
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